2020
Characteristics of Ongoing Clinical Trials for Alcohol Use Disorder Registered on ClinicalTrials.gov
Wallach JD, Krystal JH, Ross JS, O’Malley S. Characteristics of Ongoing Clinical Trials for Alcohol Use Disorder Registered on ClinicalTrials.gov. JAMA Psychiatry 2020, 77: 1081-1084. PMID: 32459295, PMCID: PMC7254444, DOI: 10.1001/jamapsychiatry.2020.1167.Peer-Reviewed Original Research
2017
It Is Time to Address the Crisis in the Pharmacotherapy of Posttraumatic Stress Disorder: A Consensus Statement of the PTSD Psychopharmacology Working Group
Krystal JH, Davis LL, Neylan TC, Raskind M, Schnurr PP, Stein MB, Vessicchio J, Shiner B, Gleason TD, Huang GD. It Is Time to Address the Crisis in the Pharmacotherapy of Posttraumatic Stress Disorder: A Consensus Statement of the PTSD Psychopharmacology Working Group. Biological Psychiatry 2017, 82: e51-e59. PMID: 28454621, DOI: 10.1016/j.biopsych.2017.03.007.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsClinical Trials as TopicHumansPsychopharmacologyPsychotropic DrugsStress Disorders, Post-Traumatic
2008
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews Drug Discovery 2008, 7: 426-437. PMID: 18425072, PMCID: PMC2715836, DOI: 10.1038/nrd2462.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsExcitatory Amino Acid AntagonistsGlutamatesHumansMood DisordersPsychotropic DrugsConceptsGlutamatergic systemMood disordersAntidepressant effectsNMDA antagonistsDouble-blind placebo-controlled crossover studyTreatment-resistant major depressive disorderPlacebo-controlled crossover studyGlutamate release inhibitorSignificant antidepressant effectNMDA receptor expressionRecurrent mental illnessSingle intravenous doseMajor depressive disorderPotential novel therapeuticsGlutamatergic abnormalitiesCrossover studyGlutamate releaseIntravenous doseMood stabilizersDepressive disorderReceptor expressionReceptor modulatorsEvidence of alterationsCerebrospinal fluidAMPA potentiators
2007
Pediatric psychopharmacology: mood, anxiety and disruptive behavior/pervasive developmental disorders
McDougle CJ, Krystal JH. Pediatric psychopharmacology: mood, anxiety and disruptive behavior/pervasive developmental disorders. Psychopharmacology 2007, 191: 1-3. PMID: 17476481, DOI: 10.1007/s00213-007-0720-4.Peer-Reviewed Original Research
2005
Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction
D’Souza D, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH. Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biological Psychiatry 2005, 57: 594-608. PMID: 15780846, DOI: 10.1016/j.biopsych.2004.12.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultAkathisia, Drug-InducedArousalCognitionDose-Response Relationship, DrugDouble-Blind MethodDronabinolEndocrine SystemFemaleHumansInjections, IntravenousMaleMental RecallMiddle AgedMotor ActivityNeuropsychological TestsPerceptionPsychiatric Status Rating ScalesPsychotic DisordersPsychotropic DrugsSchizophreniaVerbal LearningConceptsSchizophrenia patientsAntipsychotic-treated schizophrenia patientsDelta-9-tetrahydrocannabinol effectsLong-term adverse eventsCognitive deficitsPlacebo-controlled studyDelta-9-THCTransient exacerbationAdverse eventsReceptor dysfunctionEndocrine effectsHealthy subjectsStudy participationPsychotic disordersPlasma prolactinSchizophrenia symptomsPatientsSchizophreniaCognitive effectsPerceptual alterationsDeficitsCannabisSubjectsAkathisiaExacerbation
2002
Commentary: first, do no harm. Then, do some good: ethics and human experimental psychopharmacology.
Krystal JH. Commentary: first, do no harm. Then, do some good: ethics and human experimental psychopharmacology. Israel Journal Of Psychiatry And Related Sciences 2002, 39: 89-91. PMID: 12227233.Peer-Reviewed Original Research
1994
Psychobiologic Research in Post-Traumatic Stress Disorder
Southwick S, Bremner D, Krystal J, Charney D. Psychobiologic Research in Post-Traumatic Stress Disorder. Psychiatric Clinics Of North America 1994, 17: 251-264. PMID: 7937357, DOI: 10.1016/s0193-953x(18)30112-6.Peer-Reviewed Original ResearchConceptsNeurobiologic responsesCentral nervous system depressantsCentral catecholamine functionPeripheral nervous systemPost-traumatic stress disorderSymptoms of hyperarousalSevere psychological traumaCatecholamine functionOriginal insultNoradrenergic systemMultiple symptomsDevastating disorderEffective treatmentNervous systemPTSD patientsBiologic underpinningsStress-induced changesStress disorderPhysical healthBrain imagingBiologic responseDisordersPatientsPsychological disordersPTSD
1990
Clinical studies of 5-HT function using I.V. l-Tryptophan
Price L, Charney D, Delgado P, Goodman W, Krystal J, Woods S, Heninger G. Clinical studies of 5-HT function using I.V. l-Tryptophan. Progress In Neuro-Psychopharmacology And Biological Psychiatry 1990, 14: 459-472. PMID: 2236580, DOI: 10.1016/0278-5846(90)90002-x.Peer-Reviewed Original ResearchConceptsPRL responseClinical studiesDrug actionAntidepressant drug actionLong-term treatmentSuch clinical studiesThymoleptic drugsTime-dependent fashionPlasma TrpObsessive-compulsive disorderSerum prolactinElectrophysiological findingsDepressed patientsHealthy controlsAntidepressant drugsTherapeutic effectPreclinical studiesReceptor sensitivityPanic disorderChallenge agentNeuropsychiatric diseasesNeuropsychopharmacological studiesClinical levelCompulsive disorderL-Trp